Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,658 shares of the biopharmaceutical company’s stock after acquiring an additional 1,392 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $1,276,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Royal London Asset Management Ltd. lifted its position in Alnylam Pharmaceuticals by 16.7% during the fourth quarter. Royal London Asset Management Ltd. now owns 66,803 shares of the biopharmaceutical company’s stock worth $4,703,000 after buying an additional 9,566 shares in the last quarter. Gateway Investment Advisers LLC lifted its position in Alnylam Pharmaceuticals by 17.3% during the fourth quarter. Gateway Investment Advisers LLC now owns 4,531 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 667 shares in the last quarter. Meeder Asset Management Inc. lifted its position in Alnylam Pharmaceuticals by 332.9% during the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 263 shares in the last quarter. Bailard Inc. purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at $327,000. Finally, Frontier Capital Management Co. LLC raised its position in Alnylam Pharmaceuticals by 3,071.0% in the fourth quarter. Frontier Capital Management Co. LLC now owns 197,869 shares of the biopharmaceutical company’s stock valued at $14,427,000 after purchasing an additional 191,629 shares during the period. 89.78% of the stock is currently owned by institutional investors.
ALNY has been the topic of a number of research analyst reports. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $119.00 to $126.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. ValuEngine downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. Needham & Company LLC restated a “buy” rating and issued a $135.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 8th. Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Finally, Morgan Stanley upgraded Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price objective on the stock in a report on Tuesday, March 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $127.44.
In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $88.23, for a total transaction of $1,323,450.00. Following the completion of the sale, the director now directly owns 250,633 shares of the company’s stock, valued at approximately $22,113,349.59. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 49,457 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total value of $3,461,990.00. Following the sale, the chief executive officer now directly owns 239,450 shares of the company’s stock, valued at $16,761,500. The disclosure for this sale can be found here. 3.60% of the stock is owned by corporate insiders.
Shares of NASDAQ:ALNY traded down $0.50 on Wednesday, hitting $67.63. 738,600 shares of the company’s stock were exchanged, compared to its average volume of 940,294. The stock has a market cap of $7.26 billion, a P/E ratio of -8.93 and a beta of 2.53. Alnylam Pharmaceuticals, Inc. has a 1-year low of $60.27 and a 1-year high of $124.21. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.12 and a current ratio of 9.33.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. The business had revenue of $33.29 million during the quarter, compared to analysts’ expectations of $21.60 million. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The business’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.22) EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -8.48 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Raises Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally reported by Sundance Herald and is owned by of Sundance Herald. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sundanceherald.com/2019/05/29/alnylam-pharmaceuticals-inc-alny-position-boosted-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Further Reading: What are the reasons investors use put options?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.